HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early tranexamic acid administration ameliorates the endotheliopathy of trauma and shock in an in vitro model.

AbstractBACKGROUND:
Systemic vascular endothelial injury is a consequence of trauma (T)/hemorrhagic shock (HS) which results in disturbances of coagulation, inflammation, and endothelial barrier integrity. The effect of T/HS on the endothelium (endotheliopathy of trauma [EoT]) is of intense research interest and may lead to EoT-directed therapies. Administration of tranexamic acid (TXA) in trauma patients is associated with a survival benefit and fewer complications if given early after injury. Mechanisms for this protective effect include the antifibrinolytic and anti-inflammatory effects of TXA. We hypothesized that "early" administration of TXA would abrogate vascular endothelial cell activation and injury after T/HS. This was studied in vitro.
METHODS:
Confluent human umbilical vein endothelial cells were exposed to hydrogen peroxide and/or epinephrine to stimulate post-T/HS oxidant exposure and/or sympathoadrenal activation. TXA was added 15 minutes, 60 minutes, or 120 minutes after H2O2 and/or epinephrine challenge. Endothelial cell injury was indexed by cell monolayer permeability, intracellular adhesion molecule expression, soluble thrombomodulin, syndecan release (marker for glycocalyx injury), tissue type plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and angiopoietin-2/angiopoietin-1 ratio (APO-2/APO-1).
RESULTS:
Endothelial activation and injury as indexed by permeability, ICAM expression, soluble thrombomodulin were increased by H2O2 and/or epinephrine exposure. Biomarkers of endothelial coagulation profile (tPA/PAI-1) demonstrated a profibrinolytic profile (increased tPA and tPA/PAI-1 ratio) after challenge by H2O2 and/or epinephrine. Vascular "leakiness" as indexed by APO-2/APO-1 ratio was also evident. The most profound effects were noted with H2O2/epinephrine exposure. TXA administration within 60 minutes of H2O2/epinephrine challenge abolished the adverse effects noted on the endothelial-glycocalyx "double barrier." TXA administration after 60 minutes was not protective.
CONCLUSION:
Antifibrinolytic and other protective effects of TXA administration on endothelial injury are time-dependent. This study supports the concept that the clinical efficacy of TXA administration requires "early administration."
AuthorsLawrence N Diebel, Jonathan V Martin, David M Liberati
JournalThe journal of trauma and acute care surgery (J Trauma Acute Care Surg) Vol. 82 Issue 6 Pg. 1080-1086 (06 2017) ISSN: 2163-0763 [Electronic] United States
PMID28328682 (Publication Type: Journal Article)
Chemical References
  • Angiopoietin-1
  • Angiopoietin-2
  • Antifibrinolytic Agents
  • Cell Adhesion Molecules
  • Plasminogen Activator Inhibitor 1
  • Syndecans
  • Thrombomodulin
  • Tranexamic Acid
  • Hydrogen Peroxide
  • Tissue Plasminogen Activator
  • Epinephrine
Topics
  • Angiopoietin-1 (metabolism)
  • Angiopoietin-2 (metabolism)
  • Antifibrinolytic Agents (administration & dosage, therapeutic use)
  • Cell Adhesion Molecules (metabolism)
  • Endothelium, Vascular (drug effects, injuries, physiopathology)
  • Epinephrine (pharmacology)
  • Human Umbilical Vein Endothelial Cells (drug effects, physiology)
  • Humans
  • Hydrogen Peroxide (pharmacology)
  • In Vitro Techniques
  • Plasminogen Activator Inhibitor 1 (metabolism)
  • Shock, Hemorrhagic (drug therapy, physiopathology)
  • Syndecans (metabolism)
  • Thrombomodulin (metabolism)
  • Tissue Plasminogen Activator (metabolism)
  • Tranexamic Acid (administration & dosage, therapeutic use)
  • Wounds and Injuries (drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: